CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases.
+

Cadent Therapeutics

Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities.
+

Biokine

Biokine Therapeutics is developing novel therapeutics to treat cancer. It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development.

See complete portfolio

Press Releases

2020

13

Oct

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration
06

Oct

Gamida Cell: Positive Secondary Endpoints Topline Data from Omidubicel’s Phase 3 Trial in Hematologic Malignancies
12

Oct

MinInvasive: Marketing Authorization for the Rotator Cuff Repair Device OmniCuff™ in China
21

Sep

Elicio Therapeutics: Collaboration with Moffitt Cancer Center to Study AMP-CD19 in Combination with CD19 CAR T cells
21

Sep

eXIthera: Publication of EP-7041 Data; Will Pursuit 2 Parallel EP-7041 Indications, in ECMO and in COVID-19
16

Sep

MediWound: FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

Read all Press Releases